Telix Retained Earnings from 2010 to 2025

TLX Stock   17.13  0.09  0.53%   
Telix Pharmaceuticals Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Telix Pharmaceuticals Limited retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2011-06-30
Previous Quarter
-272.8 M
Current Value
-263.7 M
Quarterly Volatility
63.1 M
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 15.9 M or Selling General Administrative of 95.4 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 40.7 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Telix Pharmaceuticals Limited over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Telix Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (263.67 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Telix Retained Earnings Regression Statistics

Arithmetic Mean(97,437,617)
Geometric Mean56,862,550
Coefficient Of Variation(101.94)
Mean Deviation85,686,874
Median(44,972,599)
Standard Deviation99,329,136
Sample Variance9866.3T
Range256.1M
R-Value(0.87)
Mean Square Error2483T
R-Squared0.77
Slope(18,249,212)
Total Sum of Squares147994.2T

Telix Retained Earnings History

2025-225.4 M
2024-237.3 M
2023-263.7 M
2022-272.8 M
2021-173.5 M
2020-93 M
2019-47.1 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-237.3 M-225.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.